Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?

Jennifer L. Jones, Edward Vincent Loftus, Jr

Research output: Contribution to journalReview article

107 Citations (Scopus)

Abstract

With the increasingly widespread use of immunosuppressive and biologic agents for the treatment of Crohn's disease and ulcerative colitis come concerns about potential long-term consequences of such therapies. Disentangling the potential confounding effects of the underlying disease, its extent, severity, duration, and behavior, and concomitant medical therapy has proven to be exceedingly difficult. Unlike the case in rheumatoid arthritis, the overwhelming preponderance of population-based evidence suggests that a diagnosis of inflammatory bowel disease (IBD) is not associated with an increased relative risk of lymphoma. However, well-designed studies that evaluate the potential modifying effect of IBD severity have yet to be performed. Although the results from hospital- and population-based studies have conflicted, the results of a recent meta-analysis suggest that patients receiving purine analogs for the treatment of IBD have a lymphoma risk ≈4-fold higher than expected. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. Nevertheless, there may be a small but real risk of lymphoma associated with these therapies. Although the relative risk of lymphoma may be elevated in association with some of the medical therapies used in the treatment of IBD, this absolute risk is low. Weighing the potential risk of lymphoma associated with select medical therapies against the risk of undertreating IBD will help physicians and patients to make more informed decisions pertaining to the medical management of IBD.

Original languageEnglish (US)
Pages (from-to)1299-1307
Number of pages9
JournalInflammatory Bowel Diseases
Volume13
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Inflammatory Bowel Diseases
Lymphoma
Biological Factors
Therapeutics
Immunosuppressive Agents
Ulcerative Colitis
Crohn Disease
Population
Meta-Analysis
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Physicians

Keywords

  • Anti-TNF agents
  • Crohn's disease
  • Infliximab
  • Lymphoma
  • Methotrexate
  • Purine analogues
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lymphoma risk in inflammatory bowel disease : Is it the disease or its treatment? / Jones, Jennifer L.; Loftus, Jr, Edward Vincent.

In: Inflammatory Bowel Diseases, Vol. 13, No. 10, 10.2007, p. 1299-1307.

Research output: Contribution to journalReview article

@article{c88da2292ad2453e845d3c4c734d8358,
title = "Lymphoma risk in inflammatory bowel disease: Is it the disease or its treatment?",
abstract = "With the increasingly widespread use of immunosuppressive and biologic agents for the treatment of Crohn's disease and ulcerative colitis come concerns about potential long-term consequences of such therapies. Disentangling the potential confounding effects of the underlying disease, its extent, severity, duration, and behavior, and concomitant medical therapy has proven to be exceedingly difficult. Unlike the case in rheumatoid arthritis, the overwhelming preponderance of population-based evidence suggests that a diagnosis of inflammatory bowel disease (IBD) is not associated with an increased relative risk of lymphoma. However, well-designed studies that evaluate the potential modifying effect of IBD severity have yet to be performed. Although the results from hospital- and population-based studies have conflicted, the results of a recent meta-analysis suggest that patients receiving purine analogs for the treatment of IBD have a lymphoma risk ≈4-fold higher than expected. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. Nevertheless, there may be a small but real risk of lymphoma associated with these therapies. Although the relative risk of lymphoma may be elevated in association with some of the medical therapies used in the treatment of IBD, this absolute risk is low. Weighing the potential risk of lymphoma associated with select medical therapies against the risk of undertreating IBD will help physicians and patients to make more informed decisions pertaining to the medical management of IBD.",
keywords = "Anti-TNF agents, Crohn's disease, Infliximab, Lymphoma, Methotrexate, Purine analogues, Ulcerative colitis",
author = "Jones, {Jennifer L.} and {Loftus, Jr}, {Edward Vincent}",
year = "2007",
month = "10",
doi = "10.1002/ibd.20211",
language = "English (US)",
volume = "13",
pages = "1299--1307",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Lymphoma risk in inflammatory bowel disease

T2 - Is it the disease or its treatment?

AU - Jones, Jennifer L.

AU - Loftus, Jr, Edward Vincent

PY - 2007/10

Y1 - 2007/10

N2 - With the increasingly widespread use of immunosuppressive and biologic agents for the treatment of Crohn's disease and ulcerative colitis come concerns about potential long-term consequences of such therapies. Disentangling the potential confounding effects of the underlying disease, its extent, severity, duration, and behavior, and concomitant medical therapy has proven to be exceedingly difficult. Unlike the case in rheumatoid arthritis, the overwhelming preponderance of population-based evidence suggests that a diagnosis of inflammatory bowel disease (IBD) is not associated with an increased relative risk of lymphoma. However, well-designed studies that evaluate the potential modifying effect of IBD severity have yet to be performed. Although the results from hospital- and population-based studies have conflicted, the results of a recent meta-analysis suggest that patients receiving purine analogs for the treatment of IBD have a lymphoma risk ≈4-fold higher than expected. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. Nevertheless, there may be a small but real risk of lymphoma associated with these therapies. Although the relative risk of lymphoma may be elevated in association with some of the medical therapies used in the treatment of IBD, this absolute risk is low. Weighing the potential risk of lymphoma associated with select medical therapies against the risk of undertreating IBD will help physicians and patients to make more informed decisions pertaining to the medical management of IBD.

AB - With the increasingly widespread use of immunosuppressive and biologic agents for the treatment of Crohn's disease and ulcerative colitis come concerns about potential long-term consequences of such therapies. Disentangling the potential confounding effects of the underlying disease, its extent, severity, duration, and behavior, and concomitant medical therapy has proven to be exceedingly difficult. Unlike the case in rheumatoid arthritis, the overwhelming preponderance of population-based evidence suggests that a diagnosis of inflammatory bowel disease (IBD) is not associated with an increased relative risk of lymphoma. However, well-designed studies that evaluate the potential modifying effect of IBD severity have yet to be performed. Although the results from hospital- and population-based studies have conflicted, the results of a recent meta-analysis suggest that patients receiving purine analogs for the treatment of IBD have a lymphoma risk ≈4-fold higher than expected. Analyses of lymphoma risk in patients receiving biologic agents directed against tumor necrosis factor-alpha are confounded by concomitant use of immunosuppressive agents in most of these patients. Nevertheless, there may be a small but real risk of lymphoma associated with these therapies. Although the relative risk of lymphoma may be elevated in association with some of the medical therapies used in the treatment of IBD, this absolute risk is low. Weighing the potential risk of lymphoma associated with select medical therapies against the risk of undertreating IBD will help physicians and patients to make more informed decisions pertaining to the medical management of IBD.

KW - Anti-TNF agents

KW - Crohn's disease

KW - Infliximab

KW - Lymphoma

KW - Methotrexate

KW - Purine analogues

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=35349027343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349027343&partnerID=8YFLogxK

U2 - 10.1002/ibd.20211

DO - 10.1002/ibd.20211

M3 - Review article

C2 - 17600819

AN - SCOPUS:35349027343

VL - 13

SP - 1299

EP - 1307

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -